Table 3 Results of meta-analysis, heterogeneity, publication bias, power analysis and prediction interval of biomarkers
Variable | Odds ratio | 95% CI, P value | Heterogeneity | P vale of publication bias based on eagers regression test | Power analysis | Prediction interval |
|---|---|---|---|---|---|---|
Hypoalbuminemia | 3.09 | 1.43–6.63, P < 0.01 | 90%, P < 0.01 | P = 0.17 | 1-b = 1 | 0.17–53.56 |
Hyperuricemia | 1.32 | 1.15–1.50, P < 0.01 | 88%, P < 0.01 | P < 0.01 | 1-b = 0.99 | 0.86–2.00 |
BUN | 1.06 | 0.97–1.15, P = 0.18 | 88%, P < 0.01 | P = 0.52 | 1-b = 0.05 | 0.38–2.91 |
CRP | 1.06 | 1.00–1.12, P = 0.04 | 98%, P < 0.01 | P = 0.36 | 1-b = 0.15 | 0.86–1.31 |
HS-CRP | 1.03 | 1.01–1.05, P = 0.01 | 50%, P = 0.04 | P < 0.01 | 1-b = 0.12 | 0.98–1.08 |
NLR | 1.10 | 1.01–1.20, P = 0.01 | 78%, P < 0.01 | P = 0.26 | 1-b = 0.46 | 0.83–1.46 |
RDW | 1.34 | 1.18–1.52, P < 0.01 | 0%, P = 0.73 | P = 0.30 | 1-b = 0.70 | 1.18–1.52 |
Lower HCT | 0.94 | 0.91–0.97, P < 0.01 | 69%, P < 0.01 | P = 0.74 | 1-b = 0.33 | 0.86–1.03 |
PLR | 1.11 | 0.99–1.24, P = 0.06 | 87%, P < 0.01 | P = 0.09 | 1-b = 0.43 | 0.70–1.77 |
GGT | 3.21 | 1.26–8.15, P = 0.01 | 91%, P < 0.01 | P = 0.06 | 1-b = 1 | 0.03–266.17 |
BNP | 8.93 | 5.99–13.30, P < 0.01 | 69%, P < 0.01 | P = 0.06 | 1-b = 1 | 2.30–34.55 |
V/CR | 2.61 | 1.93–3.53, P < 0.01 | 76%, P < 0.01 | P < 0.01 | 1-b = 1 | 0.98–6.94 |
UKIM-1 | 13.51 | 7.95–22.97, P < 0.01 | 14%, P = 0.31 | P = 0.01 | 1-b = 1 | 5.12–35.66 |
Preprocedural hyperglycemia over 140 | 1.70 | 1.34–2.15, P < 0.01 | 26%, P = 0.25 | P = 0.45 | 1-b = 1 | 0.78–3.68 |
Preprocedural hyperglycemia over 200 | 2.06 | 1.87–2.28, P < 0.01 | 0%, P = 0.90 | P = 0.30 | 1-b = 1 | 1.87–2.28 |
Cystatin-C | 20.07 | 7.26–55.46, P < 0.01 | 88%, P < 0.01 | P = 0.11 | 1-b = 1 | 0.51–776.18 |
NGAL | 31.29 | 13.72–71. 34, P < 0.01 | 73%, P < 0.01 | P < 0.01 | 1-b = 1 | 1.61–605.16 |